Haleon Updates Share Capital and Voting Rights for Disclosure Purposes

Haleon PLC ( (GB:HLN) ) has shared an update.

Haleon plc has confirmed that, as of 30 April 2026, it has 8,891,932,595 issued ordinary shares, of which 12,240,797 are held in treasury, leaving 8,879,691,798 shares carrying voting rights. This updated share capital and voting rights figure provides the key denominator for investors and other obligated parties to assess and report any notifiable holdings in line with U.K. disclosure and transparency regulations, ensuring continued clarity around Haleon’s ownership structure and governance framework.

The most recent analyst rating on (GB:HLN) stock is a Sell with a £325.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.

Spark’s Take on HLN Stock

According to Spark, TipRanks’ AI Analyst, HLN is a Neutral.

The score is driven primarily by solid financial performance (consistent free cash flow and improving profitability) and a cautiously positive earnings outlook supported by margin gains and cost savings. This is tempered by weaker near-term technical momentum and only moderate valuation support.

To see Spark’s full report on HLN stock, click here.

More about Haleon PLC

Haleon plc is a consumer health company focused on improving everyday health through a broad portfolio of over‑the‑counter products. Its six core categories span Oral Health, Vitamins, Minerals and Supplements, Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health. Flagship brands such as Sensodyne, Voltaren, Panadol, Advil and Centrum reach more than a billion consumers globally and are widely recommended by health professionals.

Average Trading Volume: 22,379,245

Technical Sentiment Signal: Sell

Current Market Cap: £30.22B

Find detailed analytics on HLN stock on TipRanks’ Stock Analysis page.